Recombinant ErbB2/Her2 (Pertuzumab Biosimilar) anticorps

N° du produit ABIN7200658

Détail du produit anti-ErbB2/Her2 (Pertuzumab Biosimilar) anticorps

Antigène: ErbB2/Her2 (Pertuzumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ErbB2/Her2 (Pertuzumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Fonction: Pertuzumab Biosimilar, Human HER2 Monoclonal Antibody

Specificité: The monoclonal antibody pertuzumab biosimilar specifically binds to the human HER2/ErbB-2/c-neu.

Attributs du produit: Recombinant humanized IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody pertuzumab biosimilar was produced in the pertuzumab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pertuzumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur ErbB2/Her2 (Pertuzumab Biosimilar)

Antigène: ErbB2/Her2 (Pertuzumab Biosimilar)

Abstract: ErbB2/Her2 (Pertuzumab Biosimilar) Produits

Classe de substances: Biosimilar

Sujet: Pertuzumab, a humanized monoclonal antibody, inhibits HER dimerization and is used for the treatment of HER2-positive metastatic breast cancer, in combination with trastuzumab and docetaxel. By binding to HER2, Pertuzumab inhibits the dimerization of HER2 with other HER receptors, resulting in slowed tumor growth.